Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe page revision tag was updated to v3.6.6, indicating a small update to the study record without altering displayed content.SummaryDifference0.0%

- Check15 days agoChange DetectedThe study record now shows a funding attribution: '2023 ( U.S. NIH Grant/Contract )', indicating NIH support for the trial. This addition updates the record to disclose the study's funding source.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5 on the page, indicating a new published revision. This reflects a maintenance/version update rather than a substantive change to the page's content.SummaryDifference0.0%

- Check36 days agoChange DetectedPlain Language Summary has been removed from the page, removing a lay-friendly overview of the trial. Readers will need to consult the more technical sections for study details.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page revision label changed from v3.6.3 to v3.6.4, indicating a new build/version of the page.SummaryDifference0.0%

- Check71 days agoChange DetectedThe page revision was updated from v3.6.0 to v3.6.3. This reflects a minor update to the page metadata rather than the study content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.